Bioventix PLC
LSE:BVXP

Watchlist Manager
Bioventix PLC Logo
Bioventix PLC
LSE:BVXP
Watchlist
Price: 3 750 GBX 1.08% Market Closed
Market Cap: 195.7m GBX
Have any thoughts about
Bioventix PLC?
Write Note

Bioventix PLC
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bioventix PLC
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Bioventix PLC
LSE:BVXP
Total Equity
ÂŁ11.4m
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
10%
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Total Equity
$236.2m
CAGR 3-Years
324%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Total Equity
$111.5m
CAGR 3-Years
-19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Total Equity
$831m
CAGR 3-Years
69%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Total Equity
ÂŁ368.8m
CAGR 3-Years
88%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Total Equity
ÂŁ548.2m
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
7%
No Stocks Found

Bioventix PLC
Glance View

Market Cap
195.7m GBX
Industry
Biotechnology

Bioventix Plc engages in the development and supply of antibodies. The company is headquartered in Farnham, Surrey and currently employs 17 full-time employees. The company went IPO on 2014-04-29. The principal activity of the Company is the development and supply of antibodies. The firm specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics, such as in automated immunoassays used in blood testing. The firm offers a portfolio of antibodies to customers for both commercial use and research and development (R&D) purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The firm also supplies antibody products and services to multinational clinical diagnostics companies. The firm sells its products through direct sales and through distributors.

BVXP Intrinsic Value
3 076.09 GBX
Overvaluation 18%
Intrinsic Value
Price

See Also

What is Bioventix PLC's Total Equity?
Total Equity
11.4m GBP

Based on the financial report for Dec 31, 2023, Bioventix PLC's Total Equity amounts to 11.4m GBP.

What is Bioventix PLC's Total Equity growth rate?
Total Equity CAGR 10Y
10%

Over the last year, the Total Equity growth was 9%. The average annual Total Equity growth rates for Bioventix PLC have been 4% over the past three years , 5% over the past five years , and 10% over the past ten years .

Back to Top